CAJ | 학술논문

目的:对我院异甘草酸镁注射液的使用情况进行调查分析,以期为临床合理用药提供参考.方法:利用信息系统调取我院2014年4月住院患者中使用异甘草酸镁注射液患者的相关信息,对适应证、用法用量、用药方案、不良反应等进行统计与分析.结果:236例使用异甘草酸镁注射液的患者中,最常见的用药原因为肝胆系统疾病合并肝功能异常(43.22%);多单独使用(71.61%);日剂量波动于0.10 ~ 0.20 g,以0.20 g居多(70.34%);115例患者用药前后血清钾分别为(4.03±0.57) mmol·L-1、(3.79±0.59) mmol·L-1,t = 3.421,P = 0.001,差异有统计学意义.结论:我院异甘草酸镁注射液的使用基本合理,提示临床应注意溶媒品种的选择,根据患者肝功能受损程度及时调整给药剂量并密切监测血清钾水平.此外,对其预防性使用的适应证尚待进一步评价.
목적:대아원이감초산미주사액적사용정황진행조사분석,이기위림상합리용약제공삼고.방법:이용신식계통조취아원2014년4월주원환자중사용이감초산미주사액환자적상관신식,대괄응증、용법용량、용약방안、불량반응등진행통계여분석.결과:236례사용이감초산미주사액적환자중,최상견적용약원인위간담계통질병합병간공능이상(43.22%);다단독사용(71.61%);일제량파동우0.10 ~ 0.20 g,이0.20 g거다(70.34%);115례환자용약전후혈청갑분별위(4.03±0.57) mmol·L-1、(3.79±0.59) mmol·L-1,t = 3.421,P = 0.001,차이유통계학의의.결론:아원이감초산미주사액적사용기본합리,제시림상응주의용매품충적선택,근거환자간공능수손정도급시조정급약제량병밀절감측혈청갑수평.차외,대기예방성사용적괄응증상대진일보평개.
Objective: To investigate and analyze the application of magnesium isoglycyrrhizinate injection in clinic, and provide the reference for rational drug use.Methods: The data of the in-patients who were treated by magnesium isoglycyrrhizinate injection in April 2014 by the hospital information system were collected and analyzed in respect of the indication, usage and dosage, therapeutic regimen and adverse reactions, etc.Results:The majority disease of 236 patients using magnesium isoglycyrrhizinate injection was hepatobiliary system disease accompanied with liver dysfunction, accounting for 43.22%. Most of the remedies were using magnesium isoglycyrrhizinate injection alone (71.61%); daily dose ranged from 0.10 g to 0.20 g, and most of the dose was 0.20 g (70.34%). The mean serum potassium concentration of 115 patients before and after treatment was (4.03 ± 0.57) mmol·L-1and (3.79 ± 0.59) mmol·L-1 respectively (t = 3.421,P = 0.001). The difference was statistically signiifcant.Conclusion:The application of magnesium isoglycyrrhizinate injection in our hospital on the whole was rational, but we should pay attention to the choice of solvent, adjust the dosage according to the liver function and monitor the serum potassium concentrations when using the magnesium isoglycyrrhizinate injection. The rationality of prophylaxis indication should be further evaluated.